IFNG and acute myeloid leukemia: To investigate in vitro IFN-γ responsiveness of AML more broadly, we studied a set of AML samples from 60 patients newly diagnosed with AML spanning a spectrum of cytogenetic and molecular abnormalities as categorized by the European LeukemiaNet 2017 (ELN 2017) AML risk classification (48).